Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer

Phase I/II clinical trial of nivolumab in combination with oligo-fractionated irradiation for unresectable advanced or recurrent gastric cancer

Abstract Background Although immune checkpoint inhibitors (ICI) targeting for PD-1 axis is a promising approach for advanced gastric cancer (GC) patients, the response rate is still limited. Induction of synergistic effect of irradiation with ICI targeting for the PD-1 axis can be an attractive stra...

Full description

Bibliographic Details
Main Authors: Kosaku Mimura, Takashi Ogata, Yuya Yoshimoto, Daisaku Yoshida, Shotaro Nakajima, Hisashi Sato, Nozomu Machida, Takanobu Yamada, Yohei Watanabe, Tomoaki Tamaki, Hirohito Fujikawa, Yasuhiro Inokuchi, Suguru Hayase, Hiroyuki Hanayama, Zenichiro Saze, Hiroyuki Katoh, Fumiaki Takahashi, Takashi Oshima, Yoshiyuki Suzuki, Koji Kono
Format: Article
Language:English
Published: Nature Portfolio 2023-08-01
Series:Communications Medicine
Online Access:https://doi.org/10.1038/s43856-023-00343-4

Internet

https://doi.org/10.1038/s43856-023-00343-4

Similar Items